Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention
Erin A. Bohula, David A. Morrow, Robert P. Giugliano, Michael A. Blazing, Ping He, Jeong-Gun Park, Sabina A. Murphy, Jennifer A. White, Y. Antero Kesaniemi, Terje R. Pedersen, Adrian J. Brady, Yale Mitchel, Christopher P. Cannon and Eugene Braunwald
In patients stabilized after acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), the TRS 2°P, a simple risk stratification tool using 9 readily available clinical characteristics, identified a strong gradient of risk for cardiovascular death, MI, or ischemic stroke and an increasingly favorable relative and absolute benefit from the addition of ezetimibe to simvastatin therapy with increasing risk profile. CABG = coronary artery bypass graft; CHF = congestive heart failure; CV = cardiovascular; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; EZ = ezetimibe; HTN = hypertension; iCVA = ischemic cerebrovascular accident; MI = myocardial infarction; PAD = peripheral artery disease; Simva = simvastatin; TRS 2°P = TIMI (Thrombolysis In Myocardial Infarction) Risk Score for Secondary Prevention.